Carfilzomib
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Carfilzomib and local guidelines before prescribing.
Proteasome inhibitor
Mechanism
Proteasome inhibitor.
Uses
Relapsed multiple myeloma.
Dosing
No dose is given in the chapters. See the BNF.
Side effects
Cardiac failure, hypertension, dyspnoea, thrombocytopenia, tumour lysis.
Interactions
Few.
Contraindications and cautions
Cardiac disease caution
Monitoring
FBC, BP, cardiac assessment
Pregnancy and breastfeeding
Avoid
Renal and hepatic impairment
No adjustment
Overdose and reversal
Supportive
Special advice
Hydrate and monitor cardiac status.
More from the textbook: uses, cautions and other points
- Infection prevention: aciclovir with bortezomib, carfilzomib or daratumumab; consider levofloxacin prophylaxis in the first 12 weeks of treatment (TEAMM trial); pneumococcal, influenza and COVID-19 vaccines; immunoglobulin replacement for recurrent serious infections with low IgG.
Haematology: Myeloma and Lymphoma - Bortezomib / carfilzomib | Proteasome inhibitors for myeloma; peripheral neuropathy and thrombocytopenia (bortezomib), cardiac and hypertensive effects (carfilzomib); aciclovir prophylaxis for shingles.
Haematology: Myeloma and Lymphoma - Relapse (almost everyone relapses): change drug class or combination - carfilzomib, pomalidomide, daratumumab or isatuximab, selinexor - and, where funded, CAR-T or bispecific antibodies directed at BCMA.
Haematology: Myeloma and Lymphoma
Where it is discussed in the book
- Haematology: Myeloma and Lymphoma (3 mentions)